Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492711 · ClinicalTrials.gov registry record · Phase 3
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
A Phase 3 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
NCT02492711: Completed Phase 3 study, sponsored by MacroGenics.
NCT02492711 is a Phase 3 study that has completed, run by MacroGenics. The registered enrollment target is 624 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02492711, a Phase 3 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.
Primary Outcome
PFS is measured from the time of randomization until first documented disease progression or death from any cause, whichever is first.
Interventions
- BIOLOGICAL Trastuzumab
- BIOLOGICAL Margetuximab
- DRUG Physician's choice of chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2015-08-24 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
What the finished NCT02492711 record still lists
NCT02492711 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT02492711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02492711 about?
NCT02492711 is a clinical study titled "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer". The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of a...
What is the current status of trial NCT02492711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2015-08-24. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT02492711?
The interventions under investigation include: Trastuzumab (BIOLOGICAL), Margetuximab (BIOLOGICAL), Physician's choice of chemotherapy. (DRUG).
Who is sponsoring clinical trial NCT02492711?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02492711's enrollment target sits among peer trials
624 587th of 2000 higher than 1,413 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI